GURUFOCUS.COM » STOCK LIST » USA » NYSE » Johnson & Johnson (NYSE:JNJ) » Definitions » EV-to-EBIT
Switch to:

Johnson & Johnson EV-to-EBIT

: 21.25 (As of Today)
View and export this data going back to 1944. Start your Free Trial

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Johnson & Johnson's Enterprise Value is $435,895 Mil. Johnson & Johnson's EBIT for the trailing twelve months (TTM) ended in Jun. 2022 was $20,515 Mil. Therefore, Johnson & Johnson's EV-to-EBIT for today is 21.25.

The historical rank and industry rank for Johnson & Johnson's EV-to-EBIT or its related term are showing as below:

JNJ' s EV-to-EBIT Range Over the Past 10 Years
Min: 10.65   Med: 17.2   Max: 27.24
Current: 21.53

During the past 13 years, the highest EV-to-EBIT of Johnson & Johnson was 27.24. The lowest was 10.65. And the median was 17.20.

JNJ's EV-to-EBIT is ranked worse than
62.89% of 671 companies
in the Drug Manufacturers industry
Industry Median: 15.96 vs JNJ: 21.53

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Johnson & Johnson's Enterprise Value for the quarter that ended in Jun. 2022 was $466,708 Mil. Johnson & Johnson's EBIT for the trailing twelve months (TTM) ended in Jun. 2022 was $20,515 Mil. Johnson & Johnson's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2022 was 4.40%.


Johnson & Johnson EV-to-EBIT Historical Data

The historical data trend for Johnson & Johnson's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Johnson & Johnson Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
EV-to-EBIT
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.02 18.65 22.24 25.42 19.68

Johnson & Johnson Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
EV-to-EBIT Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.68 21.62 19.68 21.97 22.75

Competitive Comparison

For the Drug Manufacturers - General subindustry, Johnson & Johnson's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Johnson & Johnson EV-to-EBIT Distribution

For the Drug Manufacturers industry and Healthcare sector, Johnson & Johnson's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Johnson & Johnson's EV-to-EBIT falls into.



Johnson & Johnson EV-to-EBIT Calculation

Johnson & Johnson's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=435895.495/20515
=21.25

Johnson & Johnson's current Enterprise Value is $435,895 Mil.
Johnson & Johnson's EBIT for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $20,515 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Johnson & Johnson  (NYSE:JNJ) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Johnson & Johnson's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2022 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jun. 2022 ) =EBIT / Enterprise Value (Q: Jun. 2022 )
=20515/466708.1153
=4.40 %

Johnson & Johnson's Enterprise Value for the quarter that ended in Jun. 2022 was $466,708 Mil.
Johnson & Johnson's EBIT for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $20,515 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Johnson & Johnson EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Johnson & Johnson's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Johnson & Johnson Business Description

Johnson & Johnson logo
Address
One Johnson and Johnson Plaza, New Brunswick, NJ, USA, 08933
Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women's health. Geographically, just over half of total sales are generated in the United States.
Executives
Adamczyk Darius director 855 S. MINT STREET CHARLOTTE NC 28202
Hait William officer: See Remarks ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933
Mammen Mathai officer: EVP, Pharm, R&D THERAVANCE,INC. 901 GATEWAY BLVD. SOUTH SAN FRANCISCO CA 94080
Broadhurst Vanessa officer: EVP, Global Corp Aff. ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933
Swanson James D. officer: EVP, Chief Information Officer ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933
West Nadja director 1915 REXFORD ROAD CHARLOTTE NC 28211
Decker Robert J officer: Controller, CAO ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933
Joly Hubert director C/O BEST BUY CO, INC. 7601 PENN AVENUE SOUTH RICHFIELD MN 55423
Weinberger Mark A director METLIFE, INC. 200 PARK AVENUE NEW YORK NY 10166
Hewson Marillyn A director C/O CARPENTER TECHNOLOGY CORPORATION PO BOX 14662 READING PA 19612-4662
Mongon Thibaut officer: Exec VP, WW Chair, Consumer JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933
Wengel Kathryn E officer: EVP, Chief GSC Officer JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933
Wolk Joseph J officer: Exec VP, CFO JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933
Mcevoy Ashley officer: EVP, WW Chair, Medical Devices JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933
Taubert Jennifer L officer: EVP, WW Chair, Pharmaceuticals JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933

Johnson & Johnson Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)